Efficacy of high-dose methylprednisolone and cyclophosphamide in childhood-onset systemic lupus erythematosus

Paediatrica Indonesiana

View Publication Info
 
 
Field Value
 
Title Efficacy of high-dose methylprednisolone and cyclophosphamide in childhood-onset systemic lupus erythematosus
 
Creator Trisnia, Putu Ayunda
KUmara Wati, Ketut Dewi
Witarini, Komang Ayu
Sutawan, Ida Bagus Ramajaya
Santoso, Hendra
 
Description Background Systemic lupus erythematosus (SLE) is a chronic, multisystem, autoimmune disease. Untreated SLE often become progressive and lead to increased risk of mortality. Corticosteroid and cyclophosphamide remain the treatment of choice for severe SLE. Disease activity assessed with SLE Daily Activity Index (SLEDAI).
Objective To compare the disease activity of childhood-onset severe SLE at the time of diagnosis, after completion of high dose methylprednisolone, and after three month of cyclophosphamide by using  SLEDAI.
Methods This study was conducted in the Division of Pediatric Allergy and Immunology, Department of Child Health, Udayana University/Sanglah Hospital, Denpasar, Bali. Subjects were SLE patient aged 0-18 years who had severe clinical manifestations. Subject received therapy combination of high dose methylprednisolone and cyclophosphamide every 2 weeks for six doses. SLEDAI score was assessed at the time of diagnosis, after completion of high dose methylprednisolone, and after three month of cyclophosphamide.
Results During the study period, 51 children were diagnosed as SLE. Twenty-one subjects were included for analysis. Median SLEDAI score at the time of diagnosis was 23 (range 13-39). SLEDAI score after three months of cyclophosphamide was decreased to 2 (range 0-14). Post hoc analysis with Wilcoxon signed-rank test showed the improvement of SLEDAI score at the time of diagnosis and after three months of cyclophosphamide was statistically significant  (Z=-4.016, P<0.0001).
Conclusion SLEDAI score reduced after completion of high-dose methylprednisolone and three month of cyclophosphamide therapy.
 
Publisher Indonesian Pediatric Society
 
Date 2020-04-28
 
Type info:eu-repo/semantics/article
info:eu-repo/semantics/publishedVersion
 
Format application/pdf
 
Identifier https://paediatricaindonesiana.org/index.php/paediatrica-indonesiana/article/view/2313
 
Source Paediatrica Indonesiana; Vol 60 No 3 (2020): May 2020
2338-476X
0030-9311
10.14238/pi60.3.2020
 
Language eng
 
Relation https://paediatricaindonesiana.org/index.php/paediatrica-indonesiana/article/view/2313/2018
 
Rights Copyright (c) 2020 ayunda trisnia, Ketut Dewi KUmara Wati, Komang Ayu Witarini, Ida Bagus Ramajaya Sutawan, Hendra Santoso
http://creativecommons.org/licenses/by-nc-sa/4.0
 

Contact Us

The PKP Index is an initiative of the Public Knowledge Project.

For PKP Publishing Services please use the PKP|PS contact form.

For support with PKP software we encourage users to consult our wiki for documentation and search our support forums.

For any other correspondence feel free to contact us using the PKP contact form.

Find Us

Twitter

Copyright © 2015-2018 Simon Fraser University Library